9901346-8

IPOS's copy

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 38/09 // (A61K 38/09, 31:495)

A1

(11) International Publication Number: WO 98/10781

(43) International Publication Date: 19 March 1998 (19.03.98)

(21) International Application Number: PCT/EP97/04740

(22) International Filing Date: 1 September 1997 (01.09.97)

(30) Priority Data:
(1) 60/025,990 — 12 September 1996 (12.09.96) — US
(2) 60/043,228 — 10 April 1997 (10.04.97) — US

(81) Designated States: AU, BR, CN, CZ, EE, HU, IL, IS, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(71) Applicant: (1) ASTA MEDICA AKTIENGESELLSCHAFT [DE/DE]; An der Pikardie 10, D-01277 Dresden (DE).

(72) Inventors: (1) ENGEL, Jürgen; Erlenweg 3, D-63755 Alzenau (DE). (2) REISSMANN, Thomas; Massbornstrasse 44, D-60347 Frankfurt (DE). (3) RIETHMÜLLER-WINZEN, Hilde; Mittelweg 27, D-60318 Frankfurt (DE). (4) RAWERT, Jürgen; Bezirksstrasse 27, D-63755 Alzenau (DE).

1 applⁿ.
4 Invs.

(54) Title: MEANS FOR TREATING PROSTATE HYPERTROPHY AND PROSTATE CANCER

(57) Abstract

A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with α-reductase inhibitors or α-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrolix can be administerd with α-reductase inhibitors or α-receptor blocking agents.